transparent gif


Ej inloggad.

Göteborgs universitets publikationer

The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.

Författare och institution:
Aliasghar Akhiani (Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi); Anneli Stensson (Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi); Karin Schön (Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi); Nils Y Lycke (Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi)
Publicerad i:
Scandinavian journal of immunology, 63 ( 2 ) s. 97-105
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
Safe and efficacious adjuvants are much needed to facilitate the development of mucosal vaccines. Here, we have asked whether our nontoxic vaccine adjuvant, CTA1-DD, can enhance protective immunity against Helicobacter pylori infection. Intranasal immunizations with H. pylori lysate together with CTA1-DD-adjuvant induced significant protection in C57Bl/6 mice, almost as strong as similar immunizations using cholera toxin (CT)-adjuvant. Protection remained strong even at 8 weeks postchallenge and the bacterial colonization was reduced by 20-fold compared to lysate-immunized controls. Although CTA1-DD was designed to bind to B cells, microMT mice developed significant, but lower, level of protection following immunization. Intranasal immunizations with CT adjuvant in C57Bl/6 mice resulted in the development of severe postimmunization gastritis at 2 and 8 weeks postchallenge, whereas the degree of gastritis was substantially lower in the CTA1-DD-immunized mice. Protection induced by both CTA1-DD- and CT adjuvant was associated with a strong local infiltration of CD4(+) T cells in the gastric mucosa, and recall responses to specific Ag elicited substantial IFN-gamma production, indicating Th1-dominance. These findings clearly demonstrate that CTA1-DD adjuvant is a promising candidate to be further exploited in the development of a mucosal vaccine against H. pylori infection.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Medicinska grundvetenskaper ->
Mikrobiologi inom det medicinska området
Adjuvants, Immunologic, pharmacology, Administration, Intranasal, Animals, Antibodies, Bacterial, blood, B-Lymphocytes, immunology, Bacterial Vaccines, immunology, pharmacology, Cholera Toxin, immunology, pharmacology, Cytokines, immunology, Female, Gastritis, immunology, microbiology, prevention & control, Helicobacter Infections, immunology, microbiology, prevention & control, Helicobacter pylori, immunology, Immunization, adverse effects, methods, Immunohistochemistry, Male, Mice, Mice, Inbred C57BL, Recombinant Fusion Proteins, immunology, pharmacology, Specific Pathogen-Free Organisms, Statistics, Nonparametric, Th1 Cells, immunology
Postens nummer:
Posten skapad:
2007-10-12 11:47
Posten ändrad:
2010-03-09 11:28

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007